NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.72% | 11.76% | 26.15% | -2.49% | -6.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.51% | 7.50% | 34.08% | 40.28% | 38.46% |
| Operating Income | 1.51% | -7.50% | -34.08% | -40.28% | -38.46% |
| Income Before Tax | -80.95% | -4.69% | -13.94% | -24.85% | -5.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.95% | -4.69% | -13.94% | -24.85% | -5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.95% | -4.69% | -13.94% | -24.85% | -5.61% |
| EBIT | 1.51% | -7.50% | -34.08% | -40.28% | -38.46% |
| EBITDA | 1.40% | -7.65% | -34.53% | -40.95% | -38.95% |
| EPS Basic | -70.91% | 4.74% | -1.00% | -6.02% | 8.99% |
| Normalized Basic EPS | -71.01% | 4.70% | -1.00% | -5.98% | 9.00% |
| EPS Diluted | -70.91% | 4.74% | -1.00% | -6.02% | 8.99% |
| Normalized Diluted EPS | -71.01% | 4.70% | -1.00% | -5.98% | 9.00% |
| Average Basic Shares Outstanding | 7.06% | 10.00% | 13.47% | 17.73% | 13.94% |
| Average Diluted Shares Outstanding | 7.06% | 10.00% | 13.47% | 17.73% | 13.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |